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Stimulation of epidermal growth factor (EGF) recep-
tor by ligands such as transforming growth factor 
(TGF)a may be associated with cell proliferation or 
transformation in both nevocytes and keratinocytes. 
Previously, EGF receptors have been identified within 
a variety of pigmented lesions, suggesting a possible 
responsiveness to ligands such as TGFa. In the present 
study, we characterize the intralesional expression and 
distribution of immunoreactive TGFa protein by avi-
din-biotin immunoperoxidase localization in benign 
nevi, congenital nevi, dysplastic nevi, and malignant 
melanomas. In situ hybridization techniques with 
TGFa riboprobes confirmed the constitutive produc-
tion of TGFa in all types of pigmented lesions. The 
localization of TGFa expression to nevocytes when 
T ransforming growth factor (TGF)a, a mitogenic polypeptide sharing 35% homology with epidermal growth factor (EGF), exerts its effects by binding to the EGF receptor [1]. The pro-TGFa molecule is an integral membrane £rotein and the mature peptide is 
produced by proteolytic cleavage [2] . Cultures derived from normal 
human keratinocyte lines produce TGFa [3], which acts as an auto-
crine growth factor [4]. In contrast, normal melanocytes in culture 
do not express TGFa unless stimulated by ultraviolet (UV) light [5], 
although melanoma cell lines generally show constitutive expres-
sion ofTGFa [6 - 10]. 
In the in vivo cutaneous setting, TGFa is expressed and distrib-
uted in basal keratinocytes of neonatal epidermis [3] and immunore-
active TGFa is normally present in hair follicles, eccrine sweat 
glands, and sebaceous glands [11]. TGFa is overexpressed in a vari-
ety of benign as well as neoplastic hyperproliferative disorders of the 
epidermis [12] . In VillO, elevated levels ofTGFa, but not EGF, were 
demonstrated in the urine of a melanoma patient exhibiting the sign 
of Leser-Trelat [13]. Receptors for TGFa (EGF receptor) were ele-
vated in a wide variety of cutaneous lesions in that patient, presum-
ably in response to systemic TGFa production. In a larger study of 
benign, congenital, and dysplastic nevi, EGF receptor distribution 
was documented in intralesional keratinocytes and nevocytes [14]. 
Other studies reported that the EGF receptor is either selectively 
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coupled with the previous reports of expression in 
basal keratinocytes suggests the possibility of either an 
autocrine mechanism of action for TGFa or a para-
crine interplay of TGFa between keratinocytes and 
nevocytes within melanocytic lesions. An increase in 
immunoreactive TGFa in nevocytes was noted in both 
benign and dysplastic nevi from dysplastic nevus pa-
tients, as compared to benign nevi from normal pa-
tients. Congenital nevi and malignant melanomas 
showed an intermediate and variable level of TGFa 
immunoreactivity. When coupled with previous stud-
ies the data suggest linkage of the TGFajEGF receptor 
pathway in the evolution of melanocytic lesions. Key 
words: growth factor j melanocytes jkeratinocytes j dysplastic 
nevi. ] Invest Dermato1103:707 -714, 1994 
increased in malignant melanoma*" [15] or not present [16]. 
Whereas most studies suggest that the TGFa/EGF receptor system 
is present in cells of melanocytic lineage, the in lIillo regulation of 
proliferation of nevocytes and keratinocytes within melanocytic 
lesions is undefined. 
The present study was undertaken to define and characterize the 
presence of a potential growth factor (TGFa) within the context of 
melanocytic lesions. Because several lines of evidence point to a 
selective role for TGFa and its receptor in hyperplasia and subse-
quent progression to neoplasia, we sought to evaluate intralesional 
RNA expression and protein distribution for TGFa in the develop-
ment and progression of pigmented lesions. We selected a variety of 
benign (nevocellular nevi), premalignant (dysplastic nevi, congeni-
tal nevi), and malignant (melanoma) lesions to study the possible 
role of TGFa in the evolution of melanocytic neoplasia. 
MATERIALS AND METHODS 
Sample Collection Biopsy specimens of benign nevi (n = 28), congeni-
tal nevi (n = 12), dysplastic nevi (n = 17), and primary melanomas (n = 3) 
were obtained with approval of the Vanderbilt University committee for the 
Protection of Human Subjects. Thirteen lesions were obtained from patients 
with dysplas tic nevus syndrome (DNS). Dysplastic nevi were defined by the 
histologic criteria of Elder e( 01 [17]. None of the patients with benign nevi , 
congenitaI nevi, or dysplastic nevi in this study had a melanoma at the time of 
biopsy. Nevi were removed by shave excision, punch biopsy, or excisionaI 
biopsy and were promptly fixed in 4% paraformaldehyde. 
In Situ Hybridization The TGFa clone used as a probe is a human cDNA 
fragment obtained from G. Bell (University of C hicago) inserted into the 
transcription vector pGEM7Z (Promega, Madison, WI). Sense and 
•• Moretti S, Lammers PI, Kwaspen FHL el a/: Epidermal growth factor 
receptor expression is associated with tumor progression in human melano-
cytic lesions (abstr) . ] !til/est Dermato192:485, 1989. 
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Figure 1. In litu hybridization experiments. These were done using a "S-labeled TG Fa cRN A probe. Paraffin sections were exposed for 21 d. A) Benign 
nevus removed from the axilla of a 27-year-old male. Detectable signal for TGFa is present within the nevocytes; bar, 25 f.l. B) Compound congenital nevus 
removed from the abdomen of a 14-year-old male. TGFa signal is present in most but not all ncvocytes within the dermis; bar, 25 f.l . C) Dysplastic nevus 
removed from the breast of a 47-year-old woman. Moderate TGFa signal is present in most of the nevocytes. Epidermal expression is strongest in the 
downward extension of the epidermis. Note the weak labeling of the overlying basal epidermis; bar, 25 f.l. D) Dysplastic nevus removed from the scapula of a 
25-year-old man. TGFa signal is intense in the nests of nevocytes and in the germinative layers of the associated epidermis; bar, 25 f.l. E) Adjacent "normal" 
epidermis from the lesion depicted in (D). Intense labeling is present from the germinative compartment, but is less in cells of the strarum granulosum; bar, 
25 f.l . F) Adjacent "normal" epidermis from the lesion depicted in (D). This section was reacted with 35S label sense probe. No appreciable signal is present over 
the dermis or epidermis; bar, 25 f.l. 
anti-sense RNA strands were synthesized and labeled with 35S by ill vitro 
transcription in the presence of 500 11M/guanosine triphosphate (GTP). 
cytidine-triphosphate (CTP). adenosine-5' -triphosphate (ATP). and 12 f.lM 
of 35S UTP. 40 units RNasin, 2 mM spermidine, 100 f.lM dithiothreitol. 
20 mM NaCI. 40 mM TRIS (pH 7.5). 6 mM MgCI2 • and SP6 or T7 RNA 
polymerase as previously described [18]. Hybridization was carried out at 
55·C for 18 h. Post-hybridization washes consisted of 30 min at room 
temperature in 20 f.lg/ml RNase A followed by 2 h in 0.1 X standard so-
dium citrate (SSe) at 55 · C. Slides were exposed for 21 d. developed in D-19 
for 3.5 min at 12·C. counterstained with Toluidine Blue. and examined and 
photographed under an Olympus AH2 light microscope. 
Immunohistochemistry Paraffin-embedded tissues in 6-f.lm sections 
were adhered to glass slides using 12.5 ml/l ofSta-on tissue adhesive (Surgi-
path Medical Industries. Richmond. IL). Sections were deparaffinized 
through xylene, rehydrated through a graded series of ethanols, and prein-
cuba ted in normal 10% horse semm to saturate nonspecific tissue binding 
sites. Endogeneous peroxidase activity was blocked using 0.3% H20 2 in 
methanol. The semm was blotted from the slides and the specimens were 
incubated in anti-TGFa sera (Ab-2. Oncogene. Manhasset. NY). as we have 
previously reported in human skin [19]. For negative controls. sections were 
incubated with comparable dilutions of normal sera or an unrelated mono-
clonal antisera (UPC-I0, Oncogene). In selected cases. TGFa antisera was 
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Figure 2. Immunolocalization ofTGFa in a series of benign nevi. A) Nevus removed [rom the axilla of a 43-year-old woman. Although moderate 
staining for TGFa is present in the epidermis, only minimal staining is present in the nevocytes; bar, 100 Jl. B) Nevus removed from the upper arm of a 
30-year-old female. Note the weak immunoreactivity in the epidermis and in the nevocytes; bar, 100 Jl. C) Nevus removed from the lower abdomen of a 
35-year-old woman. Although TGFa staining is prominent in the epidermis, only an occasional nevocyte shows positive immunostain.ing; bar, 100 Jl. D) 
Lentiginous compound nevus removed from the back of a 28-year-old woman. Moderate to intense staining [or TGFa is present in the nevocytes and 
epidermis. Note that nevocytes in close proximity to the epidermis show the strongest TGFa immunoreactivity; bar, 100 Jl. E) Benign compoUJ1d nevus with 
architectural changes but no cytologic atypia removed from the lower abdomen of a 41-year-old male patient with dysplastic nevus syndrome. Prominent 
TGFa immunoreactivity is present in the epidermis. Nearly allnevocytes also show intense staining for TGFa; bar, 100 Ji. F) Junctionallentiginous nevus 
removed from the shoulder of a 33-year-old woman with dysplastic nevus syndrome. Although the epidermis is positive for TGFa, the sta ining for nevocytes 
is more intense; bar, 50 Jl. 
absorbed with excess TGFa prior to immunostaining procedure to verify the 
selectivity of the antibody (Ab)-2 TGFa antisera in cutaneous sections. This 
antisera has been used previously for immunolabeling in skin [19-22] and 
does not show binding to epidermal growth factor [22], but cross-reactivity 
with other EGF-like molecules has not been ruled out. All primary antibody 
incubations were performed overnight at 4·C in a humidified chamber. 
Following incubation with the primary antibody, tissues were rinsed in 
phosphate-buffered saline (PBS) for 10 min and further incubated using the 
avidin-biotin procedure (Vectastain Mouse Elite Kit, Vector Laboratories, 
Burlingame, CA). Immunoreactive TGFa was visualized using the peroxi-
dase substrate 3-amino-9-ethyl carbazole (AEC). Sections were then rinsed 
in water, dehydrated, covers lipped in lmmu-Mount (Shandon Corp. , Pitts-
burgh, PA), and photographed using an Olympus AH Vanox light micro-
scope. The immunoprecipitate intensity in keratinocytes and nevocytes in 
each tissue section was assessed in a blinded fashion by two observers (LBN, 
OLE) to monitor for consistent immunohistochemical observations using 
the following scale: 0, no stain; 1, weakly stained; 2, moderately stained; 3, 
strongly stained; 4, intensely stained. An unpaired, two-tailed t test was used 
for statistical analysis. In all cases where lesional regions exhibited negative 
immunoreactivity, adjacent areas of eccrine sweat ducts or sebaceolls glands 
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served as positive, semi-quantitative internal controls. In addition, each 
specimen was stained on at least three separate occasions to assure reproduci-
bility of staining intensities. 
RESULTS 
In Situ Hybridization Heterogeneous gene expression for 
TGFa was detected in various types of melanocytic lesions with ill 
situ hybridization using a 35S-1abeled human TGFa antisense ribo-
probe. Benign nevi (3/6) showed moderate levels ofTGFa mR~A 
expression in nests of nevocytes (Fig IA) whereas no expr~s~lOn 
was detected in the other three (data not shown). In addition, 
equally strong expression was detected consistently in the basal, 
germinative compartment of the associated epidermis in all melano-
cytic lesions studied (Fig IE). As controls, serial sections from all 
types of nevi were hybridized with a 35S-1abeled sense TGFa probe. 
In all control cases, a negligible number of silver grains were de-
tected over nevocytes, epidermis, or the dermis (Fig IF). 
In congenital nevi, the spatial patterns ofTGFa expression were 
extremely heterogeneous (6/6 lesions). Large numbers of nevocytes 
were present in the lesions evaluated in our study. Within these 
accumulations of nevocytes, moderate labeling was detected in 
many nevocytes but negatively labeled nevocytes were interspersed 
throughout these nests of nevocytes (Fig lB). The overlying epi-
dermis as well as the perilesional epidermis showed consistent 
TGFa expression in the basal compartment. In dysplastic nevi, the 
majority of the nevocytes showed uniformly strong labeling in 5/6 
lesions (Fig IC,D). TGFa expression was not detected in one dys-
plastic nevus (data not shown). The adjacent "normal" epidermis 
showed a strong expression pattern for TGF-a in the germinative 
component (Fig IE); however, labeling in the outer more differ-
entiated layers appeared to equal the background activity (Fig IE). 
Immunohistochemical Analysis ofTGFa Protein 
Berlign Nevi: Twenty-two nevocellu lar nevi from 17 normal pa-
tients were evaluated. The average immunostaining intensity was 
rated as 1.3 ± 0.20 (Fig 3A). The typical distribution and intensity 
forTGFa in these benign nevi are depicted inFig 2A-F. Note that 
nevocytes in closest proximity to the epidermis show the strongest 
TGFa immunoreactivity. This frequently observed pattern was 
characteristic of all categories of melanocytic lesions. In six benign 
nevi, minimal to no immunoreactivity for TGFa was detected in 
nevocytes despite positive TGFa immunostaining elsewhere on the 
same section (Fig 2A). In all lesions devoid of immunoreactive 
TGFa in the intralesional epidermis and nevocytes, the adjacent 
"normal" epidermis showed positive staining in keratinocytes com-
prising the hair follicles, sebaceous, and sweat glands (data not 
shown). In the intralesional epidermis of benign nevi, the basal 
compartment showed moderate staining for TGFa (1.26 ± 0.14) 
whereas the outer more differentiated layers showed the greatest 
intensity (2.32 ± 0.15) (Fig 2A,C-E and 3A). 
In addition to the 22 benign nevi from normal patients, a subset of 
six benign nevocellular nevi were removed and evaluated from pa-
tients diagnosed as having either sporadic or familial dysplastic 
nevus syndrome. The average immunoreactivity of nevocytes in 
these benign nevi was 2.29 ± 0.35, a value twice as high as the 
pattern observed in the benign nevi of normal patients (1.00 ± 
0.20) (Fig 3B). This was significant at p < 0.001. The typical 
TGFa staining intensity of nevi from DNS patients is illustrated in 
Fig 2E,F. 
Congenital N evi: Twelve congenital nevi were evaluated from pa-
tients ranging in age from 4 to 35 years. The immunostaining in-
tensity was also quite variable, and the average nevocyte staining 
intensity was 1.77 ± 0.28 (Fig 3A). Characteristic intralesion.al 
staining is ill ustrated in Fig 4A,B,E. N evocytes in closest proximity 
to the epidermis show a slightly more intense staining for TGFa 
than the deepest dermal nevocytes. When proliferating nuclear cell 
antigen (PCNA) immunostaining was employed as a marker of cell 
division on serial sections to determine if the focal nevocytes dis-
playing the heightened TGFa immunostaining were proliferatin.g 
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Figure 3. Quantitative representation of the TGFa iInmunostain-
ing. Criteria for the immunostaining assessments are described in Materials 
and Methods. Bars, SEM; N = 22 benign nevi, N = 6 benign nevi on DNS 
patients, N = 12 congenital nevi, N = 16 dysplastic nevi. A) Compares all 
benign nevi, congenital nevi, and dysplastic nevi. B) Compares benign nevi 
from normal patients to benign nevi from dysplastic nevus syndrome pa-
tients. 
nevocytes, no correlation was noted (data not shown). An extremely 
low PCNA labeling index was present in nevocytes within all cate-
gories of lesions, indicating low proliferation of nevocytes, a finding 
confirmed recently by another group. tt Again, basal epidermal 
staining (1.67 ± 0.20) was less than the outer differentiated epider-
mal layers (2.50 ± 0.30). 
Dysplastic N evi: Sixteen dysplastic nevi were evaluated from 14 
patients. Seven of these lesions were from patients with sporadic 
dysplastic nevus syndrome and the other nine lesions were removed 
from patients with familial dysplastic nevus syndrome. The average 
TGFa immunostaining intensity for dysplastic nevi was 2.06 ± 
0.26 (Fig 3A). This average immunoreactivity was significantly 
higher (p = 0.005) than that observed in the benign nevi removed 
from normal patients but similar to the staining intensity for benign 
nevi removed from patients with dysplastic nevus syndrome (Fig 
3B). Although the grading pattern for TGFa immunostaining is 
admittedly semi-quantitative, the data suggest a trend for a higher 
TGFa immunoreactivity index associated with dysplastic nevus 
syndrome. Typical TGFa immunohistochemical staining intensity 
for dysplastic nevi is shown in Fig SA,B,D-F. Strong immuno-
staining was noted in both nevocytes and the associated epidermis 
(Fig SA,B) but not in a serial section stained with TGFa antisera 
blocked with peptide (Fig SC). 
Melanomas: A Level I malignant melanoma arising in a congenital 
nevus from a 6-month-old child was evaluated for TGFa immuno-
tt Ahmed I, Muller SA: Proliferating cell nuclear antigen expression in 
mclanocytic lesions of skin. J ItIVest Dermato/100:546, 1993. 
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Figure 4. TGFa immunostaining of congenital nevi and melanomas. AJ Congenital nevus removed from the back of a 7-year-old boy. Strong 
immunostaining for TGFa is present in both the epidermis and nevocytes in the dermis. Note that the nevocytes in closest proximity to the epidermis show a 
slightly more intense staining forTGFa; bar, 100 /1. B) Higher magnification of the congenital nevus shown in (AJ. This photo shows the intensity oflabeling 
in the nest of nevocytes nearest the epidermis; bar, 50 /1 . C) Congenital nevus removed from the temple of a 6-month-old female , which contained areas 
classified as a level I melanoma. The epidermis shows modest immunostaining in the lower layers with a greater intensity in the outermost layers. The 
nevocytes exhibit variable staining qualities ranging from weak to moderate. Intense brownish deposits represent pigment accumulations within melano-
phages in the dermis; bar, lOa /1. D) Higher magnification of same lesion depicted ill (C) showing focal areas with higher levels ofTGFa protein; bar, 50 /1. E) 
Congenital nevus removed from the buttock of an l8-year-old man. The accumulation of nevocytes located within the dermis shows a weaker staining 
intensity than the overlying epidermis. Note that nevocytes closest to the epidermis seem to exhibit slightly more intense staining for TGFa; bar, 100 /1. FJ 
Level V melanoma arising in a congenital nevus removed from the scalp of a 72-year-old woman. Invading malignant melanocytes in the deep dermis exhibit a 
variable staining intensity ranging from weak to moderate; bar, lOa /1. 
stammg. Variable staining of melanocytes ranging from weak to 
moderate was noted (Fig 4C,D). A Level 11 malignant melanoma 
removed from the foot of a 33-year-old female showed no TGFa 
immunoreactivity in either the melanocytes or the associated epi-
dermis. A Level V melanoma arising within a congenital nevus in 
the scalp of a 72-year-old female showed melanocytes with variable 
intensity (Fig 4F). Melanoma cells at the lower edges of the lesion 
showed higher TGFa staining intensity than melanoma cells in the 
central portion of the lesion. No epidermis was available for evalua-
tion in this specimen. 
DISCUSSION 
In the present study, TG Fa expression as well as the distribution of 
immunoreactive TGF-a protein was documented within a broad 
spectrum of melanocytic lesions. Using two differing techniques 
(TGFa expression and TGFa protein deposition), the data confirm 
712 NANNEY ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
Figure 5. TGFa immunostaining of dysplastic nevi. A) Dysplastic nevus removed from the axilla of a 17-year-old woman. Strong immunoreactivity is 
present in both epidermis and nevocytes; bar, 100 Jl. B) A higher magnification of the dysplastic nevus displayed in (A). Note the dysplastic features of the 
epidermis as well as the foca l patches revealing distinctly positive nevocytes; bar, 50 Jl. C) A serial section of the lesion labeled in (A). TillS section was reacted 
with TGFa antisera blocked with excess TGFa peptide. Only faint non-specific background is present; bar, 100 Jl. D) Intradermal dysplastic nevus removed 
from the chest of a 47-year-old female with dysplastic nevus syndrome. The majority of the ncvocytes display strong TGFa immunoreactivity. TGFa staining 
is equally evident in the epidermis; bar, 100 Jl. E) Dysplastic nevus removed from the chest of a 19-year-old female patient with familial dysplastic nevus 
syndrome. Both nevocytes and keratinocytes show moderate TGFa immunostaining. The darkest areas are in the endogenous melanin pigment present in this 
pigmented lesion; bar, 100 Jl. F) Dysplastic nevus removed from the axilla of a 24-year-old female patient with dysplastic nevus syndrome. Ncvocytes and 
kcratinocytes show moderate TGFa immunostaining; bar, 100 Jl. 
that this cytokine is spatially positioned to influence nevocellular 
growth. This study with dysplastic and congenital nevi was under-
taken because previous reports have noted that normal melanocytes 
can be induced by ultraviolet light to express TGFa [5], and mel an-
ocytic tumor cell lines release TGFa [6-10]. The present in lI illo 
evidence suggests that both normal and dysplastic nevocytes should 
be added to the growing number of cutaneous cell populations 
capable of TGFa expression. 
Although we have confirmed the in lIillo presence of TGFa in 
melanocytic lesions, the functional significance of this finding re-
mains unknown. Our in "illO data lend support to the intriguing 
hypothesis that nevocytes from dysplastic nevus patients exhibit 
inherent modification to their TGFa mechanism. Comparison of 
the averaged TGFa staining intensity among benign, congenital, 
and dysplastic nevi indicate a possible trend toward increased TGFa 
immunodeposition in nevi from patients with DNS. Both nevo-
cytes within dysplastic nevi and nevocytes within "benign nevi" 
from dysplastic patients showed twice the degree of immunostain-
ing observed in benign nevi from normal patients. These data are in 
agreement with Fleming et al [21], who likewise showed variability 
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in TGFa immunostaining in a smaller series of normal and dysplas-
tic nevi. In the present study, immunostaining of congenital nevi for 
TGFa was intermediate within our observed spectrum of TGFa 
immunoreactivity. These elevations in dysplastic and some congen-
ital nevocytes are consistent with the theory that increased availa-
bility ofTGFa may serve to modulate nevocyte proliferation [23-
25], migration [26,27]' or differentiation [11,28] . Such paracrine/ 
autocrine mechanisms in the TGFa/EGF receptor pathway might 
place these lesions at risk for progression to malignant melanoma. 
Equally plausible is the possibility that immunoreactive TGFa Pl'O-
tein accumulates due to its non-utilization when focal nevocytes 
begin to utilize alternative cytokine/receptor pathways such as 
bFGF [29,30] , platelet-derived growth factor (PDGF) [21], or 
MGSA [31]. 
A complicating parameter in the analysis of melanocytic lesions is 
the expression of TGFa within intralesional keratinocytes. This 
circumstance provides further evidence of the existence of either an 
autocrine TGFa feedback loop within keratinocytes [3] or an inter-
active TGFa paracrine pathway between keratinocytes and nevo-
cytes. In support of the latter possibility , ill vitro examples of kerati-
nocyte participation in melanocytic behavior have already been 
characterized from co-culturing experiments with keratinocytes 
and melanocytes. In that study, melanocytic growth was supported 
by the bFGF produced by keratinocytes [30]. The present report in 
conjunction with our previous characterization ofEGF receptors in 
melanocytic lesions [14] provides indirect evidence that the TGFa/ 
EGF receptor pathway may function in a similar manner. Further 
tissue culture studies need to be done to delineate TGFa-mediated 
keratinocyte-melanocyte interaction. 
A growing number of studies continue to suggest that the status 
of the TGFa/EGF receptor pathway caIl greatly influence the hy-
perproliferative phenotype of the epidermis. The acanthotic ap-
pearance of the intralesional epidermis associated with nevi presents 
a morphology similar to situations where human hyperproliferative 
epidermal lesions overexpress TGFa [11,32-35] and when trans-
genic mice overexpress TGFa [18,36,37]. In benign hyperprolifer-
ative lesions such as psoriasis, mRNA for TGFa is overexpressed 
and immunohistochemical staining for TGFa is greatly elevated 
[12,33]. EGF receptor levels are also greatly elevated and show 
modulation as the psoriasiform phenotype regresses [32,35] . Fur-
thermore, murine transgenic lines overexpressing TGFa have been 
characterized as having papilloma formation or sebaceous gland 
hyperplasia [18,36,37] . Taken together, these situations strongly 
suggest that TGFa is an inducer of epithelial hyperplasia in the 
intact organism and may playa key role in the epidermal alterations 
seen in melanocytic lesions. 
Several previous studies have documented the presence of the 
TGFa/EGF receptor pathway in cutaneous lesions derived from 
the melanocytic lineage. We previously reported that all types of 
benign and neoplastic melanocytic lesions showed increased immu-
noreactivity for EGF receptor [14] . Other groups using differing 
staining criteria suggested that the presence of EGF receptor may 
correlate with malignant potential** [15). Indeed our earlier report 
of elevated urinary TGFa in a melanoma patient and increased EGF 
receptors in the malignant melanocytes [13] supported this same 
hypothesis. Taken together these findings suggest that alterations in 
the TGFa/EGF receptor pathway playa role in the evolution of 
malignant lesions, conferring significance 011 the characterization 
of this cytokine pathway in dysplastic nevi. 
In conclusion, the present study has documented both expression 
and distribution of TGFa in a broad spectrum of melanocytic le-
sions. Because dysplastic nevocytes showed an increase in TGFa, 
additional work is required to assess the prognostic significance of 
elevations in TGFa in " premalignant" or dysplastic nevi. Further 
studies will need to address the ill vivo impact ofTGFa within the 
context of multiple cytokine pathways that have also been detected 
within melanocytic lesions. An increasing number of growth fac-
tors that previously have been implicated in the development and 
progression of melanoma may also exert direct effects within other 
melanocytic lesions [21 ,30]. 
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